Wednesday, January 9, 2008

Omeros Files For IPO

Seattle-based Omeros said in a filing with the SEC Wednesday afternoon that it is looking to raise up to $115M in an IPO on the NASDAQ Global Market. The firm said it is looking to trade as "OMER." The IPO is being underwritten by Deutsche Bank Securities, Pacific Growth Equities, Leerink Swann, and Needham & Company. Omeros is venture backed by ARCH Venture Partners, and is developing biopharmaceuticals focused on treating inflammation and disorders of the central nervous system. According to the firm's S-1, the company had $200,000 in revenues for the year ended 2006, and a net loss of $22.77M.